Since CDK4/6i block both normal and cancer cells in the G0/G1 phase of the cell cycle, it was firstly hypothesized that the use of these novel agents in combination with standard chemotherapies could be detrimental for the efficacy of the cancer treatment [94]. Here, CDK4 is linked to cancer.